Table 2 Clinical characteristics of the study subjects at enrollment to chronic HIV care, initiation of ART, and during follow-up in Dire Dawa, Eastern Ethiopia, January 2014
Clinical characteristics | Frequency | Percent (%) |
|---|---|---|
History of exposure to ARVs before initiation of ART | ||
Present | 19 | 2 |
Absent | 930 | 98 |
Eligibility criteria for ART initiation | ||
Clinical only | 233 | 25 |
CD4 only | 274 | 29 |
Both clinical & CD4 | 438 | 46 |
TLC* & other | 4 | 0 |
Baseline CD4 (n = 923) | ||
CD4 > 100 cells/cm3 | 641 | 69 |
CD4 ≤ 100 cells/cm3 | 282 | 31 |
Median CD4 count = 150 (IQR: 83–222) | ||
NNRTI-based first-line ART initiated to patients | ||
Nevirapine based | 563 | 59 |
Efavirenz based | 386 | 41 |
NRTI-based first-line ART initiated to patients | ||
Tenofovir based | 285 | 30 |
Zidovudine based | 136 | 14 |
Stavudine based | 528 | 56 |
Adherence when least CD4 recorded (n = 907) | ||
Good (> = 95%) | 861 | 95 |
Poor (< 95%) | 46 | 5 |
ART interruption and restart history | ||
Absent | 809 | 85 |
Present | 140 | 15 |
History of regimen change (n = 916) | ||
Absent | 469 | 51 |
Present | 447 | 49 |
Duration on ART | ||
6–24 months | 284 | 30 |
24–48 months | 278 | 29 |
≥ 48 months | 387 | 41 |
Mean duration = 44 months SD: ± 26 | ||
Status of the patient at the time of the survey | ||
Alive and on ART | 600 | 63 |
Transfer out | 206 | 22 |
Lost/drop out | 114 | 12 |
Dead | 29 | 3 |
WHO clinical staging at enrollment to pre-ART | ||
Stage I/II | 355 | 38 |
Stage III/IV | 594 | 62 |
WHO clinical staging at ART initiation | ||
Stage I/II | 274 | 29 |
Stage III/IV | 675 | 71 |